Vanda Pharma jumps after US FDA approves motion sickness drug

Shares of drugmaker Vanda Pharmaceuticals VNDA.O jump 19.6% to $8.41 premarket

VNDA said late on Tuesday that the U.S. FDA has approved its drug to prevent motion-induced vomiting

The company expects to launch the drug, Nereus, in the coming months

Motion-induced vomiting is a response triggered by mixed signals between the eyes, inner ear and body sensors during activities such as boating, driving or flying

As of last close, VNDA up 46.7% YTD